Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Comorbidity indices in hematopoietic stem cell transplantation: a new report card

Bone Marrow Transplantation volume 36, pages 475–479 (2005)Cite this article

Summary:

Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT). Patients formerly excluded from myeloablative transplant due to comorbid illnesses now receive reduced-intensity conditioning regimens; hence, the incidence of comorbid conditions in HSCT recipients is expected to increase. Comorbid grading systems developed without regard for oncology patients have been applied in retrospective fashion to HSCT patients. Two commonly used scales (Charlson Comorbidity Index and the Adult Comorbidity Inventory-27) fail to include critical information: tumor and histologic type/stage, extent of prior treatment, donor stem cell source and cell type and preparative regimen. Further, data are reported in retrospective rather than prospective fashion. Despite limitations, however, such grading systems exhibit ease and utility for evaluation and may have predictive value for patient outcome. Modifying such approaches to include additional factors and appropriate weighting of components may enable an improved comparison of techniques and study results. These scoring systems may elucidate predictors of outcome and disease natural history and enhance statistical efficiency methods of HSCT. Refined scoring could be used effectively to assign patients to differing transplant conditioning regimens, that is, myeloablative vs reduced intensity. Prospective validation of such grading systems is encouraged.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Feinstein AR . The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis 1970; 23: 455–468.

    Article  CAS  PubMed  Google Scholar 

  2. Popplewell LL, Forman SJ . Is there an upper age limit for bone marrow transplantation? Bone Marrow Transplant 2002; 29: 277–284.

    Article  CAS  PubMed  Google Scholar 

  3. Yancik R . Epidemiology of cancer in the elderly. Current status and projections for the future. Rays 1997; 22: 3–9.

    CAS  PubMed  Google Scholar 

  4. Loberiza F . Report on the state of the art in blood and marrow transplantation. Part 1 of the IBMTR/ABMTR summary slides with guide. IBMTR/ABMTR Newsletter, 2003, Vol 10, pp 7–10.

  5. Bolwell BJ . Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplantation 2003; 32: 853–861.

    Article  CAS  PubMed  Google Scholar 

  6. Zangari M, Henzlova MJ, Ahmad S et al. Predictive value of left ventricular ejection fraction in stem cell transplantation. Bone Marrow Transplant 1999; 23: 917–920.

    Article  CAS  PubMed  Google Scholar 

  7. Fujimaki K, Maruta A, Yoshida M et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow transplant 2001; 27: 307–310.

    Article  CAS  PubMed  Google Scholar 

  8. Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998–1004.

    Article  CAS  PubMed  Google Scholar 

  9. Jain B, Floreani AA, Anderson JR et al. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transplant 1996; 17: 561–568.

    CAS  PubMed  Google Scholar 

  10. Lehmann S, Isberg B, Ljungman P, Paul C . Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 187–192.

    Article  CAS  PubMed  Google Scholar 

  11. Goldberg SL, Klumpp TR, Magdalinski AJ et al. Value of the pretransplant evaluation in predicting toxic 100-day mortality among blood stem cell and bone marrow recipients. J Clin Oncol 1998; 16: 3796–3802.

    Article  CAS  PubMed  Google Scholar 

  12. Crawford SW, Fisher L . Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101: 1257–1264.

    Article  CAS  PubMed  Google Scholar 

  13. Carlson K, Backlund L, Smedmyr B et al. Pulmonary function and complications subsequent to autologous bone marrow transplantation. Bone Marrow Transplant 1994; 14: 805–811.

    CAS  PubMed  Google Scholar 

  14. Chien JW, Madtes DK, Clark JG . Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 429–435.

    Article  CAS  PubMed  Google Scholar 

  15. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  PubMed  Google Scholar 

  16. Chen PM, Liu JH, Fan FS et al. Liver disease after bone marrow transplantation – the Taiwan experience. Transplantation 1995; 59: 1139–1143.

    Article  CAS  PubMed  Google Scholar 

  17. Rozman C, Carreras E, Qian C et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75–80.

    CAS  PubMed  Google Scholar 

  18. Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281–291.

    Article  CAS  PubMed  Google Scholar 

  19. Zager RA, O’Quigley J, Zager BK et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989; 13: 210–216.

    Article  CAS  PubMed  Google Scholar 

  20. Gruss E, Bernis C, Tomas JF et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995; 15: 473–479.

    Article  CAS  PubMed  Google Scholar 

  21. Karnofsky DA, Burchenal JH . The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed). Evaluation of Chemotherapeutic Agents. Columbia University Press: New York, 1949, pp 191–205.

    Google Scholar 

  22. Zubrod Cl . Clinical investigations in cancer chemotherapy. J Chronic Dis 1958; 8: 183–190.

    Article  CAS  PubMed  Google Scholar 

  23. Weisdorf D, Bishop M, Dharan B et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Bloood Marrow Transplant 2002; 8: 213–220.

    Article  Google Scholar 

  24. Robin M, Guardiola P, Dombret H et al. Allogeneic bone marrow transplantation for acute myeloblastic leukemia in remission: risk factors for long term morbidity and mortality. Bone Marrow Transplant 2003; 31: 877–887.

    Article  CAS  PubMed  Google Scholar 

  25. Deeg HJ, Seidel K, Bruemmer B et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 1995; 15: 461–468.

    CAS  PubMed  Google Scholar 

  26. Navarro WH, Loberiza FR, Bajorunaite R et al. Impact of weight on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation (AHCT) (abstract #3342). Proc ASCO 2003; 22: 832.

    Google Scholar 

  27. Linn BS, Linn MW, Gurel L . Cumulative illness rating scale. J Am Geriatr Soc 1968; 16: 622–626.

    Article  CAS  PubMed  Google Scholar 

  28. Pool DA, Brown RA . A functional rating scale for research in physical therapy. Tex Rep Biol Med 1968; 26: 133–136.

    CAS  PubMed  Google Scholar 

  29. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM . How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003; 56: 221–229.

    Article  PubMed  Google Scholar 

  30. Extermann M . Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453–471.

    Article  CAS  PubMed  Google Scholar 

  31. Extermann M . Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35: 181–200.

    Article  CAS  PubMed  Google Scholar 

  32. Charlson ME, Pompei P, Ales KL, MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.

    Article  CAS  PubMed  Google Scholar 

  33. Mulrow CD, Gerety MB, Cornell JE et al. The relationship between disease and function and perceived health in very frail elder patients. J Am Geriatr Soc 1994; 42: 374–380.

    Article  CAS  PubMed  Google Scholar 

  34. Rochon EA, Katz JN, Morrow LA et al. Comorbid illness is associated with survival and length of hospital stay in patients with current disability. A prospective comparison of three comorbidity indices. Med Care 1996; 34: 1093–1101.

    Article  CAS  PubMed  Google Scholar 

  35. Parkerson GR, Broadhead E, Tse C . The Duke Severity of illness checklist (DOSOI) for measurement of severity and comorbidity. J Clin Epidemiol 1993; 46: 379–393.

    Article  PubMed  Google Scholar 

  36. Paleri V, Wight RG . Applicability of the adult comorbidity evaluation-27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol 2002; 116: 200–205.

    CAS  PubMed  Google Scholar 

  37. Greenfield S, Apolone G, McNeil BJ, Cleary PD . The importance of co-existent disease in the occurrence of post-operative complications and one year recovery in patients undergoing total hip replacement. Comorbidities and outcomes after hip replacement. Med Care 1993; 31: 141–154.

    Article  CAS  PubMed  Google Scholar 

  38. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ . Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002; 17: 867–876.

    Article  PubMed  Google Scholar 

  39. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA . Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 2003; 42: 125–132.

    Article  PubMed  Google Scholar 

  40. Fleming ST, Pearce KA, McDavid K, Pavlov D . The development and validation of a comorbidity index for prostate cancer among black men. J Clin Epidemiol 2003; 56: 1064–1075.

    Article  PubMed  Google Scholar 

  41. Yancik R, Wesley MN, Ries LAG et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients. A population-based study. Cancer 1998; 82: 2123–2134.

    Article  CAS  PubMed  Google Scholar 

  42. Fleming ST, Rastogi A, Dmitrienko A, Johnson KD . A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999; 37: 601–614.

    Article  CAS  PubMed  Google Scholar 

  43. Shahjahan M, Alamo J, de Lima M et al. Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission. Biol Blood Marrow Transplant 2004; 10 (Suppl 2): 12–13.

    Article  Google Scholar 

  44. Sorror ML, Maris MB, Storer B et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.

    Article  CAS  PubMed  Google Scholar 

  45. Diaconescu R, Flowers CR, Storer B et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550–1558.

    Article  CAS  PubMed  Google Scholar 

  46. Pollyea D, Artz A, Stock W et al. Clinical predictors of transplant related mortality after reduced intensity allogeneic stem cell. Blood 2004; 104 (abstract 1145).

  47. Sorror ML, Maris MB, Storb RF et al. Hematopoietic cell transplantation (Hct)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. Biol Blood Marrow Transplant 2005 (abstract #57).

  48. Black NA, Jenkinson C, Hayes JA et al. Review of outcome measures used in adult critical care. Crit Care Med 2001; 29: 2119–2124.

    Article  CAS  PubMed  Google Scholar 

  49. Extermann M, Bonetti M, Sledge GW et al. MAX2 – a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Can 2004; 40: 1193–1198.

    Article  CAS  Google Scholar 

  50. Extermann M, Chen H, Cantor AB et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Can 2002; 38: 1466–1473.

    Article  CAS  Google Scholar 

  51. Sorror M, Maris M, Baron F et al. A modified hematopoietic cell transplantation (HCT)-specific-comorbidity index. Blood 2004; 104 (abstract 1146).

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation of the University of Texas MD Anderson Cancer Center, Houston, TX, USA

    J Alamo, M Shahjahan, M de Lima & S A Giralt

  2. Department of Medicine, University Hospitals of Cleveland, the Comprehensive Cancer Center of Case Western Reserve University, Cleveland, OH, USA

    H M Lazarus

Authors
  1. J Alamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Shahjahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M de Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S A Giralt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alamo, J., Shahjahan, M., Lazarus, H. et al. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant 36, 475–479 (2005). https://doi.org/10.1038/sj.bmt.1705041

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705041

Keywords

This article is cited by

Search

Advanced search

Quick links